Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
This research aims to compare the effects of oral anticoagulation versus no anticoagulation in patients aged 55 and older who have had recent episodes of transient atrial fibrillation triggered by stress and have additional factors that increase their risk of stroke. The study is a multinational, investigator-initiated, prospective, randomized, open-label trial evaluating the impact of non-vitamin K oral anticoagulants NOACs on preventing stroke and other serious cardiovascular events. Participants will be randomly assigned to either receive one of several NOACs, such as edoxaban, apixaban, dabigatran, or rivaroxaban, prescribed by their physician for the duration of the follow-up, or to a control group that will not receive anticoagulants unless medically indicated during the study. The choice of specific NOAC and dose adjustments are determined by the prescribing doctor. The study excludes patients with certain conditions like chronic atrial fibrillation, severe kidney or liver disease, recent cardiac surgery, or bleeding risks. During the study, participants will be monitored for up to 24 months to assess the occurrence of non-hemorrhagic stroke, systemic embolism, vascular mortality, myocardial infarction, peripheral arterial thrombosis, amputation, and venous thromboembolism. Regular follow-up will include evaluation of these outcomes to measure the effectiveness and safety of anticoagulation compared to no anticoagulation. Participants will provide informed consent and remain under medical supervision throughout the trial.
Actively Recruiting
Researchers are evaluating the use of cyclical testosterone and darolutamide in adults with non-metastatic castration-resistant prostate cancer nmCRPC. The study aims to see if this combination can delay the time it takes for the cancer to spread to other parts of the body or lead to death. This research involves patients who have rising prostate-specific antigen PSA levels despite treatment with darolutamide but show no metastatic disease on conventional imaging. Participants will continue to receive androgen deprivation therapy using LHRH agonists or antagonists. They will also receive intramuscular injections of testosterone enanthate on day 1 of each 56-day cycle, with darolutamide taken orally at 600 mg twice daily from days 29 to 56 of each cycle. These treatments will continue until disease progression, unacceptable side effects, death, withdrawal, or study termination. Standard care medications like LHRH agonistsantagonists and darolutamide are provided through usual healthcare channels. Throughout the study, participants will undergo blood tests, scans including whole body bone scans and CT scans, and complete quality of life questionnaires. The main outcome measured is metastasis-free survival, tracked every 8 weeks for approximately four years. Safety and tolerability, PSA response, quality of life, hormone levels, and bone health markers will also be monitored regularly during the study, which may last around two years for some assessments.